National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 30963-30964 [2021-12138]
Download as PDF
<![CDATA[
30963
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–12150 Filed 6–9–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–XXXX]
Agency Information Collection
Request; 30-Day Public Comment
Request
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Family
Planning Annual Report 2.0.
Type of Collection: New.
OMB No.: 0990–NEW—Office of
Population Affairs.
Abstract: The Office of Population
Affairs (OPA), within the Office of the
Assistant Secretary for Health, seeks
approval for a new 3-year encounter
level data collection for the Family
Planning Annual Report (FPAR).
Currently collected in aggregate under
OMB No. 0990–0221, this new data
collection, ‘‘FPAR 2.0’’, will collect
information at the encounter level and
build on the existing data collection and
reporting system. This annual reporting
requirement is for competitively
awarded grants authorized and funded
by the Title X Family Planning Program.
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before July 12, 2021.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT:
Sherrette Funn, Sherrette.Funn@hhs.gov
or (202) 795–7714. When submitting
comments or requesting information,
please include the document identifier
0990–New–30D and project title for
reference.
Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
SUPPLEMENTARY INFORMATION:
Office of the Secretary, HHS.
ACTION: Notice.
AGENCY:
In compliance with the
requirement of the Paperwork
SUMMARY:
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
Type of respondent
Average
burden per
response
(in hours)
Total
burden
hours
Grantees ..........................................................................................................
70
1
102
7140
Total ..........................................................................................................
70
1
102
7140
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2021–12113 Filed 6–9–21; 8:45 am]
BILLING CODE 4150–34–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
khammond on DSKJM1Z7X2PROD with NOTICES
Number
responses per
respondent
VerDate Sep<11>2014
19:52 Jun 09, 2021
Jkt 253001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Clinical Trials SEP (UG3, U24, R61, R34).
Date: July 21, 2021.
E:\FR\FM\10JNN1.SGM
10JNN1
30964
Federal Register / Vol. 86, No. 110 / Thursday, June 10, 2021 / Notices
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–J,
Bethesda, MD 20892, (301) 827–7085,
zhihong.shan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2021–12142 Filed 6–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley; tel. 240–669–5092;
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Understanding and Reducing Cardiovascular
Disease in Type 1 Diabetes Mellitus.
Date: July 15, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 208–
Z, Bethesda, MD 20892, (301) 827–7987,
susan.sunnarborg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
17:15 Jun 09, 2021
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
ACTION:
[FR Doc. 2021–12138 Filed 6–9–21; 8:45 am]
VerDate Sep<11>2014
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Jkt 253001
FRugally Optimized DNA Octamer
(FRODO): DNA Vector and Uses
Thereof for Detecting HIV and SIV
Description of Technology
Quantitative polymerase chain
reactions (qPCRs) are commonly
employed to enumerate genes of interest
among particular biological samples.
Insertion of PCR amplicons into plasmid
DNA is a mainstay for creation of
known quantities of target sequences to
standardize quantitative PCRs.
Typically, one amplicon is inserted into
one plasmid construct, the plasmid is
then amplified, purified, serially
diluted, and then quantified to be used
to enumerate target sequences in
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
unknown samples. As qPCR is often
used to detect multiple amplicons
simultaneously, individual qPCR
standards are often desired to be
normalized one to another. Unlike prior
methods using separate plasmid
constructs for each target sequence,
FRODO incorporates eight amplicons
into one plasmid construct ensuring
equivalent template copy numbers for
all amplicons. Amplifying, purifying,
diluting and quantifying one plasmid
construct rather than eight individual
constructs streamlines standard curve
qPCR analyses, reducing reagents and
simplifying normalization between
amplicons.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Clinical Detection, Monitoring of
Nucleic Acid Markers of HIV and
Immunological Health: FRODO may be
used to efficiently quantify target
sequences in unknown samples.
• FRODO is a single plasmid
containing 8 amplicons which can be
used to quantify several different strains
of SIV and HIV, cell number equivalents
for humans and nonhuman primates, T
cell receptor excision circles (humans
and nonhuman primates), and bacterial
16S and ampicillin resistance DNA.
• FRODO may offer improved, more
affordable, highly-sensitive nucleic
acid-based HIV quantification and/or
diagnostic response times, enhancing
patient treatment and interventions.
• FRODO can be used to quantify
levels of bacterial DNA in clinical
samples to determine potential sepsis.
• This technology is especially useful
in translational HIV research in which
human and nonhuman primate models
are used to study HIV pathogenesis,
informing public health responses.
Competitive Advantages
• A simplified workflow for qPCR
testing. Amplifying, purifying, diluting
and quantifying one plasmid construct
rather than multiple, individual
constructs streamlines standard curve
qPCR analyses, reducing reagents and
simplifying normalization between
amplicons.
• At present, there are a number of
antibody-based clinical tools that may
be used for diagnosing/detecting HIV,
but there are fewer products that
affordably detect/monitor nucleic acids
of HIV within cells, and immunological
health, and efficacy of medicaments
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30963-30964]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12138]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Clinical Trials SEP (UG3, U24, R61, R34).
Date: July 21, 2021.
[[Page 30964]]
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD, Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 205-J, Bethesda, MD 20892, (301) 827-7085,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: June 4, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-12138 Filed 6-9-21; 8:45 am]
BILLING CODE 4140-01-P
